BioSpace News Archive

Benitec Biopharma Inc., a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference “Silence and Replace” platform, announced it closed its previously announced underwritten public offering of 15,544,041 shares of its common stock and accompanying warrants to purchase up to 15,544,041 shares of common stock.

Researchers at The Jackson Laboratory have created a panel of genetically diverse mice that accurately model the highly variable human response to SARS-CoV-2 infection.

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to three new employees.

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the second quarter ending June 30, 2023, and provided an update on recent program and corporate developments.

Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading fabless integrated circuit design company and product solution provider in China, today announced that it will report its unaudited financial results for the first half of 2023 before the U.S. market opens on Tuesday, August 15, 2023.

Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the second quarter of 2023.

Senti Biosciences, Inc., a biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases using its proprietary Gene Circuit platform, reported financial results for the second quarter of 2023.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced financial results for the second quarter ended June 30, 2023.